Introduction: While various antiplatelet regimens are currently available for secondary
prevention after ischemic stroke, data comparing their efficacy and safety are scarce. We …

Background Antiplatelet drugs may prevent recurrent ischemic events after ischemic stroke
but their relative effectiveness and harms still need to be clarified. Within this network meta …

Background The current guidelines recommend various antiplatelet agents used alone or in
combination for secondary prevention of noncardioembolic stroke. Objective The purpose of …

New studies have refined the role of antiplatelet therapy in secondary prevention after
noncardioembolic strokes. The first line antiplatelet therapy remains Aspirin. Clopidogrel …

Patients with transient ischemic attack (TIA) or ischemic stroke carry a risk of recurrent stroke
of between 5% and 20% per year. In patients with TIA or ischemic stroke of non-cardiac …

Abstract Purpose of Review Antiplatelet therapy remains the standard of care in secondary
stroke prevention for non-cardioembolic ischemic stroke and transient ischemic attack. We …

In 2004, approximately 9 million people worldwide experienced a stroke, with the majority
being ischemic in nature. While the prognosis for recovery can be good, long-term survival …

Purpose of review This narrative review critically evaluated the published studies regarding
the systematic use of antiplatelet agents for secondary stroke prevention. Recent findings …

Antiplatelet therapy is one of the mainstays for secondary stroke prevention. This narrative
review aimed to highlight the current evidence and recommendations of antiplatelet therapy …

Background Several clinical trials reported that clopidogrel was superior to aspirin in
secondary stroke prevention by reducing the risk of major adverse cardiovascular events …